Combivir (Stat Rx USA)
Welcome to the PulseAid listing for the Combivir drug offered from Stat Rx USA. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Stat Rx USA |
NON-PROPRIETARY NAME: | lamivudine, zidovudine |
SUBSTANCE NAME: | LAMIVUDINE; ZIDOVUDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1997-09-30 |
END MARKETING DATE: | 0000-00-00 |
Combivir HUMAN PRESCRIPTION DRUG Details:
Item Description | Combivir from Stat Rx USA |
LABELER NAME: | Stat Rx USA |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150; 300(mg/1; mg/1) |
START MARKETING DATE: | 1997-09-30 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 16590-061_0692a48c-af11-43a4-9b2c-d3493bb23138 |
PRODUCT NDC: | 16590-061 |
APPLICATION NUMBER: | NDA020857 |
Other LAMIVUDINE; ZIDOVUDINE Pharmaceutical Manufacturers / Labelers: